Table 2.
Association of Frequent Genotype Combinations (>5%) with Primary and Secondary Outcome Measures of Ondansetron Treatment Responsea
| Combination | Genotype Combination | Population Carrying the Genotype Combination (% in Total Cohort) | Estimated Mean Difference (95% CI) and p-Value | ||
|---|---|---|---|---|---|
| DDD | PHDD | PDA | |||
| 1 |
Possessing only one of the three identified HTR3 genotypes: (HTR3A-rs1150226-AG alone or HTR3B-rs17614942-AC alone or HTR3A-rs1176713-GG alone) |
O=15/133 P=16/138 (11%) |
−2 35 (−4.41 to −0.29) 0.025 |
−19.05% (−37.73% to −0.36%) 0.046 |
16.12% (−2.49% to 34.74%) (0.090) |
| 2 |
Possessing a combination of any two of the three identified HTR3 genotypes: (HTR3A-rs1150226-AG & HTR3B-rs17614942-AC or HTR3A-rs1176713-GG & HTR3B-rs17614942-AC) |
O=14/133 P=18/138 (12%) |
−2 65 (−4.65 to −0.66) 0.009 |
−22.43% (−40.77% to −4.09%) 0.017 |
20.23% (2.06% to 38.40%) 0.029 |
| 3 |
Possessing any one, two, or all three of the identified HTR3 genotypes: (i.e., HTR3A-rs1150226-AG &/or HTR3A-rs1176713-GG &/or HTR3B-rs17614942-AC) |
O=29/133 P=34/138 (23%) |
−2.50 (−3.92 to −1.08) 0.0006 |
−20.58% (−33.53% to −7.62%) 0.002 |
18.18% (5.26% to 31.10%) 0.006 |
| 4 |
Possessing any one, two, three, or all four of the identified HTR3 and SLC6A4 genotypes: (SLC6A4-LL/TT &/or HTR3A-rs1150226-AG &/or HTR3A-rs1176713-GG &/or HTR3B-rs17614942-AC) |
O=41/133 P=51/138 (34%) |
−1.71 (−2.88 to −0.54) 0.004 |
−11.13% (−21.94% to −0.31%) 0.044 |
11.57% (0.81% to 22.33%) 0.035 |
a
All comparisons are between the ondansetron and placebo groups and are listed in descending order of magnitude of their DDD reductions; mean differences for DDD are in standard drinks; negative values indicate improvement from baseline.
CI=confidence interval; O=ondansetron; P=placebo; DDD=drinks per drinking day; PHDD=percentage of heavy drinking days; PDA=percentage of days abstinent.